首页 > 最新文献

Drug Resistance Updates最新文献

英文 中文
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer 小细胞肺癌获得塔拉他单抗耐药后分子亚型的变化。
IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-26 DOI: 10.1016/j.drup.2024.101198
Hyung-Min Ahn , Seog-Yun Park , Yura Choi , Jaemin Kim , Youngjoo Lee
Tarlatamab, a novel bispecific T-cell engager, has demonstrated unprecedented efficacy in patients with small cell lung cancer. However, there is no known mechanism of resistance to tarlatamab. This study suggests that a transcriptional expression shift might be associated with acquired resistance to tarlatamab.
Tarlatamab是一种新型的双特异性t细胞结合剂,在小细胞肺癌患者中显示出前所未有的疗效。然而,对塔拉他单抗的耐药机制尚不清楚。这项研究表明,转录表达转移可能与获得性塔拉他单抗耐药性有关。
{"title":"Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer","authors":"Hyung-Min Ahn ,&nbsp;Seog-Yun Park ,&nbsp;Yura Choi ,&nbsp;Jaemin Kim ,&nbsp;Youngjoo Lee","doi":"10.1016/j.drup.2024.101198","DOIUrl":"10.1016/j.drup.2024.101198","url":null,"abstract":"<div><div>Tarlatamab, a novel bispecific T-cell engager, has demonstrated unprecedented efficacy in patients with small cell lung cancer. However, there is no known mechanism of resistance to tarlatamab. This study suggests that a transcriptional expression shift might be associated with acquired resistance to tarlatamab.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"79 ","pages":"Article 101198"},"PeriodicalIF":15.8,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma 3'tRF-AlaAGC的n6 -甲基腺苷修饰通过促进胃癌肿瘤微环境中乳酸的积累而削弱PD-1的阻断作用。
IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-26 DOI: 10.1016/j.drup.2024.101197
Weiguo Xu , Bin Zhou , Ping Wang , Yuyan Ma , Yu Jiang , Dongping Mo , Jun Wu , Jingjing Ma , Xiao Wang , Yinxing Miao , Yong Nian , Junyu Zheng , Jie Li , Feng Yan , Gang Li
The balance between CD8+ T cells and regulatory T (Treg) cells in the tumor microenvironment (TME) plays a crucial role in the immune checkpoint inhibition (ICI) therapy in gastric carcinoma (GC). However, related factors leading to the disturbance of TME and resistance to ICI therapy remain unknown. In this study, we applied N6-methyladenosine (m6A) small RNA Epitranscriptomic Microarray and screened out 3'tRF-AlaAGC based on its highest differential expression level and lowest inter-group variance. N6-methyladenosine modification significantly enhanced the stability of 3'tRF-AlaAGC, which strengthened glycolysis and lactic acid (LA) production in GC cells by binding to PTBP1 (Polypyrimidine Tract Binding Protein 1). In the peritoneal GC implantation model established in huPBMC-NCG mice, 3'tRF-AlaAGC significantly increased the proportion of PD1+ Treg cells. Furthermore, in high-LA environments driven by glucose consumption of GC cells, Treg cells actively uptake LA through MCT1, facilitating NFAT1 translocation into the nucleus and enhancing PD1 expression, whereas PD1 expression by effector T cell is diminished. Meanwhile, T cell suppression assays were performed under low-LA or high-LA conditions, and the proliferation of CD8+ T cells was dampened by adding Sintilimab in a high-LA but not in a low-LA environment, suggesting the preferential activation of PD1+ Treg cell. These findings deciphered the complexities of the immune microenvironment in GC, providing prospects for identifying robust biomarkers that could improve the evaluation of therapeutic effectiveness and prognosis in immune therapy for GC.
肿瘤微环境(TME)中CD8+ T细胞和调节性T (Treg)细胞之间的平衡在胃癌(GC)免疫检查点抑制(ICI)治疗中起着至关重要的作用。然而,导致TME紊乱和对ICI治疗耐药的相关因素尚不清楚。本研究采用n6 -甲基腺苷(m6A)小RNA Epitranscriptomic Microarray技术,根据3'tRF-AlaAGC的最高差异表达水平和最低组间方差筛选出3'tRF-AlaAGC。n6 -甲基腺苷修饰显著增强了3'tRF-AlaAGC的稳定性,通过与PTBP1 (polypy嘧啶束结合蛋白1)结合,增强了GC细胞的糖酵解和乳酸(LA)生成。在huPBMC-NCG小鼠腹膜GC植入模型中,3'tRF-AlaAGC显著增加了PD1+ Treg细胞的比例。此外,在GC细胞葡萄糖消耗驱动的高LA环境中,Treg细胞通过MCT1积极摄取LA,促进NFAT1易位进入细胞核,增强PD1表达,而效应T细胞的PD1表达减少。同时,在低la和高la条件下进行T细胞抑制实验,在高la环境下添加Sintilimab可以抑制CD8+ T细胞的增殖,而在低la环境下则没有,提示PD1+ Treg细胞优先活化。这些发现揭示了GC中免疫微环境的复杂性,为鉴定强大的生物标志物提供了前景,这些生物标志物可以改善GC免疫治疗的疗效评估和预后。
{"title":"N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma","authors":"Weiguo Xu ,&nbsp;Bin Zhou ,&nbsp;Ping Wang ,&nbsp;Yuyan Ma ,&nbsp;Yu Jiang ,&nbsp;Dongping Mo ,&nbsp;Jun Wu ,&nbsp;Jingjing Ma ,&nbsp;Xiao Wang ,&nbsp;Yinxing Miao ,&nbsp;Yong Nian ,&nbsp;Junyu Zheng ,&nbsp;Jie Li ,&nbsp;Feng Yan ,&nbsp;Gang Li","doi":"10.1016/j.drup.2024.101197","DOIUrl":"10.1016/j.drup.2024.101197","url":null,"abstract":"<div><div>The balance between CD8<sup>+</sup> T cells and regulatory T (Treg) cells in the tumor microenvironment (TME) plays a crucial role in the immune checkpoint inhibition (ICI) therapy in gastric carcinoma (GC). However, related factors leading to the disturbance of TME and resistance to ICI therapy remain unknown. In this study, we applied N6-methyladenosine (m6A) small RNA Epitranscriptomic Microarray and screened out 3'tRF-AlaAGC based on its highest differential expression level and lowest inter-group variance. N6-methyladenosine modification significantly enhanced the stability of 3'tRF-AlaAGC, which strengthened glycolysis and lactic acid (LA) production in GC cells by binding to <em>PTBP1</em> (Polypyrimidine Tract Binding Protein 1). In the peritoneal GC implantation model established in huPBMC-NCG mice, 3'tRF-AlaAGC significantly increased the proportion of PD1<sup>+</sup> Treg cells. Furthermore, in high-LA environments driven by glucose consumption of GC cells, Treg cells actively uptake LA through <em>MCT1</em>, facilitating <em>NFAT1</em> translocation into the nucleus and enhancing PD1 expression, whereas PD1 expression by effector T cell is diminished. Meanwhile, T cell suppression assays were performed under low-LA or high-LA conditions, and the proliferation of CD8<sup>+</sup> T cells was dampened by adding Sintilimab in a high-LA but not in a low-LA environment, suggesting the preferential activation of PD1<sup>+</sup> Treg cell. These findings deciphered the complexities of the immune microenvironment in GC, providing prospects for identifying robust biomarkers that could improve the evaluation of therapeutic effectiveness and prognosis in immune therapy for GC.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"79 ","pages":"Article 101197"},"PeriodicalIF":15.8,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research progress on gene mutations and drug resistance in leukemia 白血病基因突变与耐药研究进展。
IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-26 DOI: 10.1016/j.drup.2024.101195
Xiangyu Ma , Jiamin Xu , Yanan Wang , Joshua S. Fleishman , Hao Bing , Boran Yu , Yanming Li , Letao Bo , Shaolong Zhang , Zhe-Sheng Chen , Libo Zhao
Leukemia is a type of blood cancer characterized by the uncontrolled growth of abnormal cells in the bone marrow, which replace normal blood cells and disrupt normal blood cell function. Timely and personalized interventions are crucial for disease management and improving survival rates. However, many patients experience relapse following conventional chemotherapy, and increasing treatment intensity often fails to improve outcomes due to mutated gene-induced drug resistance in leukemia cells. This article analyzes the association of gene mutations and drug resistance in leukemia. It explores genetic abnormalities in leukemia, highlighting recently identified mutations affecting signaling pathways, cell apoptosis, epigenetic regulation, histone modification, and splicing mechanisms. Additionally, the article discusses therapeutic strategies such as molecular targeting of gene mutations, alternative pathway targeting, and immunotherapy in leukemia. These approaches aim to combat specific drug-resistant mutations, providing potential avenues to mitigate leukemia relapse. Future research with these strategies holds promise for advancing leukemia treatment and addressing the challenges of drug-resistant mutations to improve patient outcomes.
白血病是一种血癌,其特征是骨髓中异常细胞不受控制地生长,这些细胞取代了正常的血细胞,破坏了正常的血细胞功能。及时和个性化的干预措施对于疾病管理和提高生存率至关重要。然而,许多患者在常规化疗后出现复发,并且由于白血病细胞中基因突变引起的耐药,增加治疗强度往往不能改善结果。本文分析了基因突变与白血病耐药的关系。它探讨了白血病的遗传异常,强调了最近发现的影响信号通路、细胞凋亡、表观遗传调控、组蛋白修饰和剪接机制的突变。此外,本文还讨论了白血病的治疗策略,如基因突变的分子靶向、替代途径靶向和免疫治疗。这些方法旨在对抗特定的耐药突变,为减轻白血病复发提供了潜在的途径。这些策略的未来研究有望推进白血病治疗,并解决耐药突变的挑战,以改善患者的预后。
{"title":"Research progress on gene mutations and drug resistance in leukemia","authors":"Xiangyu Ma ,&nbsp;Jiamin Xu ,&nbsp;Yanan Wang ,&nbsp;Joshua S. Fleishman ,&nbsp;Hao Bing ,&nbsp;Boran Yu ,&nbsp;Yanming Li ,&nbsp;Letao Bo ,&nbsp;Shaolong Zhang ,&nbsp;Zhe-Sheng Chen ,&nbsp;Libo Zhao","doi":"10.1016/j.drup.2024.101195","DOIUrl":"10.1016/j.drup.2024.101195","url":null,"abstract":"<div><div>Leukemia is a type of blood cancer characterized by the uncontrolled growth of abnormal cells in the bone marrow, which replace normal blood cells and disrupt normal blood cell function. Timely and personalized interventions are crucial for disease management and improving survival rates. However, many patients experience relapse following conventional chemotherapy, and increasing treatment intensity often fails to improve outcomes due to mutated gene-induced drug resistance in leukemia cells. This article analyzes the association of gene mutations and drug resistance in leukemia. It explores genetic abnormalities in leukemia, highlighting recently identified mutations affecting signaling pathways, cell apoptosis, epigenetic regulation, histone modification, and splicing mechanisms. Additionally, the article discusses therapeutic strategies such as molecular targeting of gene mutations, alternative pathway targeting, and immunotherapy in leukemia. These approaches aim to combat specific drug-resistant mutations, providing potential avenues to mitigate leukemia relapse. Future research with these strategies holds promise for advancing leukemia treatment and addressing the challenges of drug-resistant mutations to improve patient outcomes.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"79 ","pages":"Article 101195"},"PeriodicalIF":15.8,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Silent circulation of plasmid-borne tet(X6) and blaOXA-58 genes in a community-acquired Acinetobacter baumannii strain 一株社区获得性鲍曼不动杆菌质粒携带的tet(X6)和blaOXA-58基因的沉默循环
IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-25 DOI: 10.1016/j.drup.2024.101194
Huiqiong Jia , Qingchao Tong , Le Wang , Yuye Wu , Xinyang Li , Shuangshuang Li , Yingying Kong , Yingying Zhang , João Pedro Rueda Furlan , Nwai Oo Khine , Patrick Butaye , Jun Zhang , Qing Yang , Zhi Ruan
To characterize the genomic features of a community-acquired Acinetobacter baumannii strain, co-carrying tet(X6) and blaOXA-58 genes, but was susceptible to tigecycline and carbapenems. The tet(X6) and blaOXA-58 genes were found on a 149,518 bp non-conjugative plasmid. The blaOXA-58 gene was silent, due to the presence of an intact ISAba3-like element upstream, which rendered the strain susceptible to carbapenems.
研究一株社区获得性鲍曼不动杆菌的基因组特征,该菌株共携带tet(X6)和blaOXA-58基因,但对替加环素和碳青霉烯类药物敏感。在149,518 bp的非共轭质粒上发现了tet(X6)和blaOXA-58基因。blaOXA-58基因是沉默的,由于上游存在一个完整的类似于isaba3的元件,这使得该菌株对碳青霉烯类敏感。
{"title":"Silent circulation of plasmid-borne tet(X6) and blaOXA-58 genes in a community-acquired Acinetobacter baumannii strain","authors":"Huiqiong Jia ,&nbsp;Qingchao Tong ,&nbsp;Le Wang ,&nbsp;Yuye Wu ,&nbsp;Xinyang Li ,&nbsp;Shuangshuang Li ,&nbsp;Yingying Kong ,&nbsp;Yingying Zhang ,&nbsp;João Pedro Rueda Furlan ,&nbsp;Nwai Oo Khine ,&nbsp;Patrick Butaye ,&nbsp;Jun Zhang ,&nbsp;Qing Yang ,&nbsp;Zhi Ruan","doi":"10.1016/j.drup.2024.101194","DOIUrl":"10.1016/j.drup.2024.101194","url":null,"abstract":"<div><div>To characterize the genomic features of a community-acquired <em>Acinetobacter baumannii</em> strain, co-carrying <em>tet</em>(X6) and <em>bla</em><sub>OXA-58</sub> genes, but was susceptible to tigecycline and carbapenems. The <em>tet</em>(X6) and <em>bla</em><sub>OXA-58</sub> genes were found on a 149,518 bp non-conjugative plasmid. The <em>bla</em><sub>OXA-58</sub> gene was silent, due to the presence of an intact IS<em>Aba3</em>-like element upstream, which rendered the strain susceptible to carbapenems.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"79 ","pages":"Article 101194"},"PeriodicalIF":15.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142889253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wip1 phosphatase activator QGC-8–52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells Wip1磷酸酶激活剂QGC-8-52特异性地使p53阴性癌细胞对化疗增敏,同时保护正常细胞。
IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-24 DOI: 10.1016/j.drup.2024.101196
Ke Wu , Xiao-xiao Ge , Xiao-fan Duan , Jie-qing Li , Kun Wang , Qiao-Hong Chen , Zhi-min Huang , Wei-yan Zhang , Yong Wu , Qun Li
PP2C serine-threonine phosphatase Wip1 plays an important role in normal tissue homeostasis, stress signaling and pathogenesis of various human diseases. It is an attractive drug target for cancer treatment and inhibition of its expression or activity constitute a novel therapeutic intervention strategy to prevent the development of various cancers. However, previous strategies for Wip1 suppression may be ineffective in cancers lacking p53. Here, we have characterized the activity of a novel Wip1 phosphatase activator, QGC-8–52, in preclinical models of breast malignancies. QGC-8–52 significantly sensitizes the cancer cell lines with p53 deletion to chemotherapeutic agents. This effect was mediated by the Wip1-FOXO3a interaction and subsequent dephosphorylation of Thr487 that resulted, in response to anticancer treatment, in enhancing the transcription activity of FOXO3a on the proapoptotic TRAIL gene. The sensitizing effect of Wip1 activation on chemotherapeutic drugs only targeted cancer cells lacking p53. The activation of Wip1 in normal cells provided protection from anticancer drug-induced apoptosis by reducing the strength of upstream signaling to p53. Therefore, during the treatment of anticancer drugs, the activated Wip1 phosphatase boosts the apoptosis of p53-negative tumors and protects normal tissues. Our findings may represent an effective and safe therapeutic strategy for cancers with p53 deletion.
PP2C丝氨酸-苏氨酸磷酸酶Wip1在正常组织稳态、应激信号传导和多种人类疾病的发病机制中发挥重要作用。它是一种有吸引力的癌症治疗药物靶点,抑制其表达或活性是预防各种癌症发展的一种新的治疗干预策略。然而,先前的Wip1抑制策略在缺乏p53的癌症中可能无效。在这里,我们描述了一种新的Wip1磷酸酶激活剂QGC-8-52在乳腺恶性肿瘤临床前模型中的活性。QGC-8-52对p53缺失的癌细胞对化疗药物有明显的增敏作用。这种作用是由Wip1-FOXO3a相互作用和随后Thr487的去磷酸化介导的,在抗癌治疗的反应中,FOXO3a对促凋亡TRAIL基因的转录活性增强。Wip1激活对化疗药物的增敏作用仅针对缺乏p53的癌细胞。在正常细胞中,Wip1的激活通过降低p53上游信号的强度,为抗癌药物诱导的细胞凋亡提供保护。因此,在抗癌药物治疗过程中,激活的Wip1磷酸酶促进p53阴性肿瘤的凋亡,保护正常组织。我们的研究结果可能为p53缺失的癌症提供了一种有效和安全的治疗策略。
{"title":"Wip1 phosphatase activator QGC-8–52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells","authors":"Ke Wu ,&nbsp;Xiao-xiao Ge ,&nbsp;Xiao-fan Duan ,&nbsp;Jie-qing Li ,&nbsp;Kun Wang ,&nbsp;Qiao-Hong Chen ,&nbsp;Zhi-min Huang ,&nbsp;Wei-yan Zhang ,&nbsp;Yong Wu ,&nbsp;Qun Li","doi":"10.1016/j.drup.2024.101196","DOIUrl":"10.1016/j.drup.2024.101196","url":null,"abstract":"<div><div>PP2C serine-threonine phosphatase Wip1 plays an important role in normal tissue homeostasis, stress signaling and pathogenesis of various human diseases. It is an attractive drug target for cancer treatment and inhibition of its expression or activity constitute a novel therapeutic intervention strategy to prevent the development of various cancers. However, previous strategies for Wip1 suppression may be ineffective in cancers lacking p53. Here, we have characterized the activity of a novel Wip1 phosphatase activator, QGC-8–52, in preclinical models of breast malignancies. QGC-8–52 significantly sensitizes the cancer cell lines with p53 deletion to chemotherapeutic agents. This effect was mediated by the Wip1-FOXO3a interaction and subsequent dephosphorylation of Thr487 that resulted, in response to anticancer treatment, in enhancing the transcription activity of FOXO3a on the proapoptotic <em>TRAIL</em> gene. The sensitizing effect of Wip1 activation on chemotherapeutic drugs only targeted cancer cells lacking p53. The activation of Wip1 in normal cells provided protection from anticancer drug-induced apoptosis by reducing the strength of upstream signaling to p53. Therefore, during the treatment of anticancer drugs, the activated Wip1 phosphatase boosts the apoptosis of p53-negative tumors and protects normal tissues. Our findings may represent an effective and safe therapeutic strategy for cancers with p53 deletion.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"79 ","pages":"Article 101196"},"PeriodicalIF":15.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142958365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
WITHDRAWN: Low miR-224-5p in exosomes confers colorectal cancer 5-FU resistance by upregulating S100A4 外泌体中的低miR-224-5p通过上调S100A4赋予结直肠癌5-FU抗性
IF 24.3 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-16 DOI: 10.1016/j.drup.2024.101193
Yan-yan Yan, Zhuo-fen Deng, Xing-tao Wu, Yu Lu, Zhuang-yan Zhu, Qing Wen, Wei Zhang, Hai-yan Zhang, Xin-zhu Chen, Yu-song Wu, Xue-bing He, Zi-ang Ma, Jin-shuo Li, Hong Bi, Jian-ye Zhang
{"title":"WITHDRAWN: Low miR-224-5p in exosomes confers colorectal cancer 5-FU resistance by upregulating S100A4","authors":"Yan-yan Yan, Zhuo-fen Deng, Xing-tao Wu, Yu Lu, Zhuang-yan Zhu, Qing Wen, Wei Zhang, Hai-yan Zhang, Xin-zhu Chen, Yu-song Wu, Xue-bing He, Zi-ang Ma, Jin-shuo Li, Hong Bi, Jian-ye Zhang","doi":"10.1016/j.drup.2024.101193","DOIUrl":"https://doi.org/10.1016/j.drup.2024.101193","url":null,"abstract":"","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"4 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142889235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of idealized amphiphiles and protease inhibitors: Conferring antimicrobial peptides with stable antibacterial activity under physiological conditions to combat multidrug-resistant bacteria 理想的两亲体和蛋白酶抑制剂的关联:赋予抗菌肽在生理条件下具有稳定的抗菌活性,以对抗多重耐药细菌。
IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-09 DOI: 10.1016/j.drup.2024.101183
Yongjie Zhu , Bowen Li , Wanying Xu, Yuanmengxue Wang, Guoyu Li, Chongpeng Bi, Anshan Shan, Changxuan Shao

Aims

The unstable antimicrobial activity of antimicrobial peptides (AMPs) under physiological conditions (especially the degradation instigated proteases) seems to be a persistent impediment for their successful implementation in clinical trials. Consequently, our objective was to devise AMP engineering frameworks that could sustain robust antibacterial efficacy within physiological environments.

Methods

In this work, we harvested AMPs with stable antimicrobial activity under the physiological barriers through the combination of idealized amphiphiles and trypsin inhibitors.

Results

We screened and identified the lead peptides IK3-A and IK3-S, which showed potent activity against Gram-negative bacteria, including multidrug-resistant (MDR) bacteria, and exhibited promising biocompatibility with mammalian cells. Remarkably, IK3-A and IK3-S maintained sustained antibacterial potency under physiological salts, serum, and protease conditions. Furthermore, both IK3-A and IK3-S kill Gram-negative bacteria by attacking the bacterial cell membrane and inducing oxidative damage (at high concentrations). Crucially, IK3-A and IK3-S have optimal safety and efficacy in mice.

Conclusions

This is the first work to compare the effects of different trypsin inhibitors on the resistance of AMPs to protease hydrolysis on the same sequence platform. In conclusion, these findings provide guidance for the molecular design of AMPs with stable antibacterial activity under physiological conditions and facilitates the process of clinical translation of AMPs as antimicrobial biomaterials against MDR bacteria. Moreover, this may stimulate a more general interest in protease inhibitors as molecular scaffolds in the creation of highly stable peptide-based biomaterials.
目的:抗菌肽(AMPs)在生理条件下不稳定的抗菌活性(尤其是降解引发的蛋白酶)似乎是其在临床试验中成功实施的持续障碍。因此,我们的目标是设计AMP工程框架,可以在生理环境中保持强大的抗菌功效。方法:通过理想的两亲体与胰蛋白酶抑制剂的结合,在生理屏障下获得具有稳定抗菌活性的抗菌肽。结果:我们筛选并鉴定了IK3-A和IK3-S先导肽,它们对革兰氏阴性菌(包括耐多药细菌)具有有效的活性,并且与哺乳动物细胞具有良好的生物相容性。值得注意的是,IK3-A和IK3-S在生理盐、血清和蛋白酶条件下保持了持续的抗菌效力。此外,IK3-A和IK3-S通过攻击细菌细胞膜并诱导氧化损伤(高浓度)杀死革兰氏阴性细菌。关键是,IK3-A和IK3-S在小鼠中具有最佳的安全性和有效性。结论:本文首次比较了不同胰蛋白酶抑制剂对AMPs在同一序列平台上的蛋白酶水解抗性的影响。综上所述,这些发现为生理条件下抗菌活性稳定的抗菌肽分子设计提供了指导,并促进了抗菌肽作为耐多药耐药细菌抗菌生物材料的临床转化过程。此外,这可能会激发人们对蛋白酶抑制剂作为制造高度稳定的肽基生物材料的分子支架的更普遍的兴趣。
{"title":"Association of idealized amphiphiles and protease inhibitors: Conferring antimicrobial peptides with stable antibacterial activity under physiological conditions to combat multidrug-resistant bacteria","authors":"Yongjie Zhu ,&nbsp;Bowen Li ,&nbsp;Wanying Xu,&nbsp;Yuanmengxue Wang,&nbsp;Guoyu Li,&nbsp;Chongpeng Bi,&nbsp;Anshan Shan,&nbsp;Changxuan Shao","doi":"10.1016/j.drup.2024.101183","DOIUrl":"10.1016/j.drup.2024.101183","url":null,"abstract":"<div><h3>Aims</h3><div>The unstable antimicrobial activity of antimicrobial peptides (AMPs) under physiological conditions (especially the degradation instigated proteases) seems to be a persistent impediment for their successful implementation in clinical trials. Consequently, our objective was to devise AMP engineering frameworks that could sustain robust antibacterial efficacy within physiological environments.</div></div><div><h3>Methods</h3><div>In this work, we harvested AMPs with stable antimicrobial activity under the physiological barriers through the combination of idealized amphiphiles and trypsin inhibitors.</div></div><div><h3>Results</h3><div>We screened and identified the lead peptides IK3-A and IK3-S, which showed potent activity against Gram-negative bacteria, including multidrug-resistant (MDR) bacteria, and exhibited promising biocompatibility with mammalian cells. Remarkably, IK3-A and IK3-S maintained sustained antibacterial potency under physiological salts, serum, and protease conditions. Furthermore, both IK3-A and IK3-S kill Gram-negative bacteria by attacking the bacterial cell membrane and inducing oxidative damage (at high concentrations). Crucially, IK3-A and IK3-S have optimal safety and efficacy in mice.</div></div><div><h3>Conclusions</h3><div>This is the first work to compare the effects of different trypsin inhibitors on the resistance of AMPs to protease hydrolysis on the same sequence platform. In conclusion, these findings provide guidance for the molecular design of AMPs with stable antibacterial activity under physiological conditions and facilitates the process of clinical translation of AMPs as antimicrobial biomaterials against MDR bacteria. Moreover, this may stimulate a more general interest in protease inhibitors as molecular scaffolds in the creation of highly stable peptide-based biomaterials.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"79 ","pages":"Article 101183"},"PeriodicalIF":15.8,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why and how citrate may sensitize malignant tumors to immunotherapy 柠檬酸盐为何以及如何使恶性肿瘤对免疫疗法敏感
IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-26 DOI: 10.1016/j.drup.2024.101177
Philippe Icard , Mathilde Prieto , Antoine Coquerel , Ludovic Fournel , Joseph Gligorov , Johanna Noel , Adrien Mouren , Anthony Dohan , Marco Alifano , Luca Simula
Immunotherapy, either alone or in combination with chemotherapy, has demonstrated limited efficacy in a variety of solid cancers. Several factors contribute to explaining primary or secondary resistance. Among them, cancer cells, whose metabolism frequently relies on aerobic glycolysis, promote exhaustion of cytotoxic immune cells by diverting the glucose in the tumor microenvironment (TME) to their own profit, while secreting lactic acid that sustains the oxidative metabolism of immunosuppressive cells. Here, we propose to combine current treatment based on the use of immune checkpoint inhibitors (ICIs) with high doses of sodium citrate (SCT) because citrate inhibits cancer cell metabolism (by targeting both glycolysis and oxidative metabolism) and may active anti-tumor immune response. Indeed, as showed in preclinical studies, SCT reduces cancer cell growth, promoting cell death and chemotherapy effectiveness. Furthermore, since the plasma membrane citrate carrier pmCIC is mainly expressed in cancer cells and low or not expressed in immune and non-transformed cells, we argue that the inhibition of cancer cell metabolism by SCT may increase glucose availability in the TME, thus promoting functionality of anti-tumor immune cells. Concomitantly, the decrease in the amount of lactic acid in the TME may reduce the functionality of immunosuppressive cells. Preclinical studies have shown that SCT can enhance the anti-tumor immune response through an enhancement of T cell infiltration and activation, and a repolarization of macrophages towards a TAM1-like phenotype. Therefore, this simple and cheap strategy may have a major impact to increase the efficacy of current immunotherapies in human solid tumors and we encourage testing it in clinical trials.
免疫疗法,无论是单独使用还是与化疗联合使用,在多种实体癌中的疗效都很有限。原发性或继发性抗药性的产生有多种因素。其中,癌细胞的新陈代谢经常依赖有氧糖酵解,它们通过将肿瘤微环境(TME)中的葡萄糖转用于自身获利,同时分泌乳酸维持免疫抑制细胞的氧化代谢,从而促进细胞毒性免疫细胞的衰竭。在此,我们建议将目前基于使用免疫检查点抑制剂(ICIs)的治疗方法与大剂量柠檬酸钠(SCT)相结合,因为柠檬酸钠能抑制癌细胞代谢(通过靶向糖酵解和氧化代谢),并能活跃抗肿瘤免疫反应。事实上,正如临床前研究显示的那样,SCT 可减少癌细胞生长,促进细胞死亡,提高化疗效果。此外,由于质膜柠檬酸载体 pmCIC 主要在癌细胞中表达,而在免疫细胞和非转化细胞中表达较低或不表达,我们认为 SCT 对癌细胞代谢的抑制可能会增加 TME 中葡萄糖的可用性,从而促进抗肿瘤免疫细胞的功能。同时,TME 中乳酸量的减少可能会降低免疫抑制细胞的功能。临床前研究表明,SCT 可以通过增强 T 细胞的浸润和活化,以及使巨噬细胞向 TAM1 样表型的再极化来增强抗肿瘤免疫反应。因此,这种简单而廉价的策略可能会对提高当前免疫疗法在人类实体瘤中的疗效产生重大影响,我们鼓励在临床试验中进行测试。
{"title":"Why and how citrate may sensitize malignant tumors to immunotherapy","authors":"Philippe Icard ,&nbsp;Mathilde Prieto ,&nbsp;Antoine Coquerel ,&nbsp;Ludovic Fournel ,&nbsp;Joseph Gligorov ,&nbsp;Johanna Noel ,&nbsp;Adrien Mouren ,&nbsp;Anthony Dohan ,&nbsp;Marco Alifano ,&nbsp;Luca Simula","doi":"10.1016/j.drup.2024.101177","DOIUrl":"10.1016/j.drup.2024.101177","url":null,"abstract":"<div><div>Immunotherapy, either alone or in combination with chemotherapy, has demonstrated limited efficacy in a variety of solid cancers. Several factors contribute to explaining primary or secondary resistance. Among them, cancer cells, whose metabolism frequently relies on aerobic glycolysis, promote exhaustion of cytotoxic immune cells by diverting the glucose in the tumor microenvironment (TME) to their own profit, while secreting lactic acid that sustains the oxidative metabolism of immunosuppressive cells. Here, we propose to combine current treatment based on the use of immune checkpoint inhibitors (ICIs) with high doses of sodium citrate (SCT) because citrate inhibits cancer cell metabolism (by targeting both glycolysis and oxidative metabolism) and may active anti-tumor immune response. Indeed, as showed in preclinical studies, SCT reduces cancer cell growth, promoting cell death and chemotherapy effectiveness. Furthermore, since the plasma membrane citrate carrier pmCIC is mainly expressed in cancer cells and low or not expressed in immune and non-transformed cells, we argue that the inhibition of cancer cell metabolism by SCT may increase glucose availability in the TME, thus promoting functionality of anti-tumor immune cells. Concomitantly, the decrease in the amount of lactic acid in the TME may reduce the functionality of immunosuppressive cells. Preclinical studies have shown that SCT can enhance the anti-tumor immune response through an enhancement of T cell infiltration and activation, and a repolarization of macrophages towards a TAM1-like phenotype. Therefore, this simple and cheap strategy may have a major impact to increase the efficacy of current immunotherapies in human solid tumors and we encourage testing it in clinical trials.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"78 ","pages":"Article 101177"},"PeriodicalIF":15.8,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer 阻断嘌呤代谢可逆转巨噬细胞免疫抑制,增强非小细胞肺癌的抗肿瘤免疫力
IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-23 DOI: 10.1016/j.drup.2024.101175
Li Yang , Aitian Li , Weina Yu , Huishang Wang , Lei Zhang , Dan Wang , Ying Wang , Ru Zhang , Qingyang Lei , Zhangnan Liu , Shanshan Zhen , Haiming Qin , Yaqing Liu , Yang Yang , Xian-Lu Song , Yi Zhang

Aims

Immune checkpoint blockade therapy is not effective in most patients with non-small cell lung cancer (NSCLC) due to the immunosuppressive tumor microenvironment. Macrophages are key components of tumor-infiltrating immune cells and play a critical role in immunosuppression, which can be mediated by cell-intrinsic metabolism. This study aimed to evaluate whether macrophages regulate NSCLC progression through metabolic crosstalk with cancer cells and affect immunotherapy efficacy.

Methods

The macrophage landscape of NSCLC tissues were analyzed by single-cell sequencing and verified through flow cytometry and immunofluorescence. Multiplex assay, single-cell sequencing data, ELISA, immunofluorescence, and RNA-seq et al. were used to investigate and verify the mechanism of macrophage-mediated metabolic regulation on immunosuppression. The tumor-bearing model was established in C57BL/6 J mice to explore in vivo efficacy.

Results

We found that tumor tissue-derived macrophages exhibited an anti-inflammatory phenotype and had a prognostic value for NSCLC. NSCLC cell-secreted CXCL8 recruited macrophages from peritumor tissues to tumor sites and promoted programmed death-ligand 1 (PD-L1) expression by activating purine metabolism with increasing xanthine dehydrogenase and uric acid production. Moreover, purine metabolism-mediated macrophage immunosuppression was dependent on NLRP3/caspase-1/IL-1β signaling. Blockade of purine metabolism signaling enhanced anti-tumor immunity and the efficacy of anti-PD-L1 therapy.

Conclusions

Collectively, our findings reveal a key role of purine metabolism in macrophage immunosuppression and suggest that blockade of purine metabolism combined with immune checkpoint blockade could provide synergistic effects in NSCLC treatment.
目的 由于肿瘤微环境具有免疫抑制作用,免疫检查点阻断疗法对大多数非小细胞肺癌(NSCLC)患者无效。巨噬细胞是肿瘤浸润免疫细胞的关键组成部分,在免疫抑制中发挥着关键作用,而免疫抑制可由细胞内在代谢介导。本研究旨在评估巨噬细胞是否通过与癌细胞的代谢串扰调控NSCLC的进展并影响免疫疗法的疗效。方法通过单细胞测序分析NSCLC组织的巨噬细胞情况,并通过流式细胞术和免疫荧光进行验证。采用多重检测、单细胞测序数据、ELISA、免疫荧光和RNA-seq等方法研究和验证巨噬细胞介导的代谢调控对免疫抑制的作用机制。结果我们发现,肿瘤组织来源的巨噬细胞表现出抗炎表型,对 NSCLC 有预后价值。NSCLC 细胞分泌的 CXCL8 将巨噬细胞从肿瘤周围组织招募到肿瘤部位,并通过激活嘌呤代谢,增加黄嘌呤脱氢酶和尿酸的产生,促进程序性死亡配体 1(PD-L1)的表达。此外,嘌呤代谢介导的巨噬细胞免疫抑制依赖于NLRP3/caspase-1/IL-1β信号传导。总之,我们的研究结果揭示了嘌呤代谢在巨噬细胞免疫抑制中的关键作用,并表明阻断嘌呤代谢与免疫检查点阻断相结合可在NSCLC治疗中产生协同效应。
{"title":"Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer","authors":"Li Yang ,&nbsp;Aitian Li ,&nbsp;Weina Yu ,&nbsp;Huishang Wang ,&nbsp;Lei Zhang ,&nbsp;Dan Wang ,&nbsp;Ying Wang ,&nbsp;Ru Zhang ,&nbsp;Qingyang Lei ,&nbsp;Zhangnan Liu ,&nbsp;Shanshan Zhen ,&nbsp;Haiming Qin ,&nbsp;Yaqing Liu ,&nbsp;Yang Yang ,&nbsp;Xian-Lu Song ,&nbsp;Yi Zhang","doi":"10.1016/j.drup.2024.101175","DOIUrl":"10.1016/j.drup.2024.101175","url":null,"abstract":"<div><h3>Aims</h3><div>Immune checkpoint blockade therapy is not effective in most patients with non-small cell lung cancer (NSCLC) due to the immunosuppressive tumor microenvironment. Macrophages are key components of tumor-infiltrating immune cells and play a critical role in immunosuppression, which can be mediated by cell-intrinsic metabolism. This study aimed to evaluate whether macrophages regulate NSCLC progression through metabolic crosstalk with cancer cells and affect immunotherapy efficacy.</div></div><div><h3>Methods</h3><div>The macrophage landscape of NSCLC tissues were analyzed by single-cell sequencing and verified through flow cytometry and immunofluorescence. Multiplex assay, single-cell sequencing data, ELISA, immunofluorescence, and RNA-seq et al. were used to investigate and verify the mechanism of macrophage-mediated metabolic regulation on immunosuppression. The tumor-bearing model was established in C57BL/6 J mice to explore in vivo efficacy.</div></div><div><h3>Results</h3><div>We found that tumor tissue-derived macrophages exhibited an anti-inflammatory phenotype and had a prognostic value for NSCLC. NSCLC cell-secreted CXCL8 recruited macrophages from peritumor tissues to tumor sites and promoted programmed death-ligand 1 (PD-L1) expression by activating purine metabolism with increasing xanthine dehydrogenase and uric acid production. Moreover, purine metabolism-mediated macrophage immunosuppression was dependent on NLRP3/caspase-1/IL-1β signaling. Blockade of purine metabolism signaling enhanced anti-tumor immunity and the efficacy of anti-PD-L1 therapy.</div></div><div><h3>Conclusions</h3><div>Collectively, our findings reveal a key role of purine metabolism in macrophage immunosuppression and suggest that blockade of purine metabolism combined with immune checkpoint blockade could provide synergistic effects in NSCLC treatment.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"78 ","pages":"Article 101175"},"PeriodicalIF":15.8,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-translational modifications in drug resistance 抗药性中的翻译后修饰
IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-21 DOI: 10.1016/j.drup.2024.101173
Chenggui Miao , Yurong Huang , Cheng Zhang , Xiao Wang , Bing Wang , Xinyue Zhou , Yingqiu Song , Peng Wu , Zhe-Sheng Chen , Yibin Feng
Resistance to antitumor drugs, antimicrobial drugs, and antiviral drugs severely limits treatment effectiveness and cure rate of diseases. Protein post-translational modifications (PTMs) represented by glycosylation, ubiquitination, SUMOylation, acetylation, phosphorylation, palmitoylation, and lactylation are closely related to drug resistance. PTMs are typically achieved by adding sugar chains (glycosylation), small proteins (ubiquitination), lipids (palmitoylation), or functional groups (lactylation) to amino acid residues. These covalent additions are usually the results of signaling cascades and could be reversible, with the triggering mechanisms depending on the type of modifications. PTMs are involved in antitumor drug resistance, not only as inducers of drug resistance but also as targets for reversing drug resistance. Bacteria exhibit multiple PTMs-mediated antimicrobial drug resistance. PTMs allow viral proteins and host cell proteins to form complex interaction networks, inducing complex antiviral drug resistance. This review summarizes the important roles of PTMs in drug resistance, providing new ideas for exploring drug resistance mechanisms, developing new drug targets, and guiding treatment plans.
抗肿瘤药物、抗菌药物和抗病毒药物的抗药性严重限制了疾病的治疗效果和治愈率。以糖基化、泛素化、SUMOylation、乙酰化、磷酸化、棕榈酰化和乳酰化为代表的蛋白质翻译后修饰(PTM)与耐药性密切相关。PTM 通常是通过在氨基酸残基上添加糖链(糖基化)、小蛋白(泛素化)、脂质(棕榈酰化)或功能基团(乳化)来实现的。这些共价添加通常是信号级联的结果,可能是可逆的,触发机制取决于修饰的类型。PTMs 与抗肿瘤药物耐药性有关,不仅是耐药性的诱因,也是逆转耐药性的靶点。细菌表现出多种 PTMs 介导的抗菌药物耐药性。PTMs 使病毒蛋白质和宿主细胞蛋白质形成复杂的相互作用网络,诱导复杂的抗病毒药物耐药性。本综述总结了 PTMs 在耐药性中的重要作用,为探索耐药机制、开发新的药物靶点和指导治疗方案提供了新思路。
{"title":"Post-translational modifications in drug resistance","authors":"Chenggui Miao ,&nbsp;Yurong Huang ,&nbsp;Cheng Zhang ,&nbsp;Xiao Wang ,&nbsp;Bing Wang ,&nbsp;Xinyue Zhou ,&nbsp;Yingqiu Song ,&nbsp;Peng Wu ,&nbsp;Zhe-Sheng Chen ,&nbsp;Yibin Feng","doi":"10.1016/j.drup.2024.101173","DOIUrl":"10.1016/j.drup.2024.101173","url":null,"abstract":"<div><div>Resistance to antitumor drugs, antimicrobial drugs, and antiviral drugs severely limits treatment effectiveness and cure rate of diseases. Protein post-translational modifications (PTMs) represented by glycosylation, ubiquitination, SUMOylation, acetylation, phosphorylation, palmitoylation, and lactylation are closely related to drug resistance. PTMs are typically achieved by adding sugar chains (glycosylation), small proteins (ubiquitination), lipids (palmitoylation), or functional groups (lactylation) to amino acid residues. These covalent additions are usually the results of signaling cascades and could be reversible, with the triggering mechanisms depending on the type of modifications. PTMs are involved in antitumor drug resistance, not only as inducers of drug resistance but also as targets for reversing drug resistance. Bacteria exhibit multiple PTMs-mediated antimicrobial drug resistance. PTMs allow viral proteins and host cell proteins to form complex interaction networks, inducing complex antiviral drug resistance. This review summarizes the important roles of PTMs in drug resistance, providing new ideas for exploring drug resistance mechanisms, developing new drug targets, and guiding treatment plans.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"78 ","pages":"Article 101173"},"PeriodicalIF":15.8,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug Resistance Updates
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1